Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LENTI-RV-01
- Development stage
- Preclinical
- Lead developer
- Theravectys
- Modality
- Vaccines & Immunotherapeutics
01
Overview
LENTI-RV-01 is a lentiviral vector-based prophylactic vaccine candidate under development by Theravectys for the prevention of Rift Valley fever. Utilizing Theravectys's proprietary lentiviral vector platform, the vaccine is designed to deliver genetic material encoding Rift Valley fever virus antigens directly to dendritic cells in vivo. This targeted delivery stimulates robust, long-lasting cellular (T-cell) and humoral (antibody) immune responses to protect against Rift Valley fever virus infection. The program is currently in the discovery stage.
Beyond the preview
Go deeper on LENTI-RV-01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LENTI-RV-01.